LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Trial Profile

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Betamethasone-dipropionate/calcipotriol (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms PSO-FAST
  • Sponsors LEO Pharma
  • Most Recent Events

    • 12 Jul 2016 According to Leo Pharma media release, based on the results from PSO-FAST study and a phase II MUSE trial (Profile 217861), the company has launched Enstilar foam spray for psoriasis in the United Kingdom.
    • 26 Apr 2016 According to Leo Pharma media release, based on the results from this PSO-FAST study and other MUSE trial (see CTP 700217861), the company received marketing authorisation for Enstilar (calcipotriol/betamethasone dipropionate) for the topical treatment of plaque psoriasis in patients 18 years of age or older, in the United Kingdom.
    • 21 Mar 2016 Results published in a Leo Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top